Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a EV/EBITDA of 23.9×. Over the past ten years it has ranged from 0.0× (June 2025) to 938× (June 2018); the current reading is higher than 59% of that period. That is above the Biotechnology industry median of 0.6× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 25.0× —
FY2024 0.0× —
FY2023 23.8× 67.49%
FY2022 14.2× (17.31%)
FY2021 17.2× (8.47%)
FY2020 18.7× (54.08%)
FY2019 40.8× (27.54%)
FY2018 56.3× (71.78%)
FY2017 200× (19.40%)
FY2016 248× —

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 23.7× 8.97%
Mar 2026 21.8× (13.05%)
Dec 2025 25.0× 11.43%
Sep 2025 22.5× (14.47%)
42 more quarters

Against its own ten years

Low 0.0× High 938×
Ten-year median 20.0×
Current reading's percentile 59

EV/EBITDA against peers

Company EV/EBITDA
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
REGN Regeneron Pharmaceuticals, Inc. compare 17.6×
RPRX Royalty Pharma PLC compare 22.9×
VRTX Vertex Pharmaceuticals Incorporated 23.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 27.2×
ARGX argenex SE compare 29.6×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 34.6×
Biotechnology industry median 0.6×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on VRTX